Therapeutic Applications of Selective and Non-Selective Inhibitors of Monoamine Oxidase A and B that do not Cause Significant Tyramine Potentiation

NeuroToxicology

Volumn 25, Issue 1-2, 2004, Pages 243-250

  Youdim, Moussa B H ^a   Weinstock, Marta ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Anti Parkinson drugs; Antidepressants; Moclobemide; Monoamine oxidase A and B; Rasagiline; RIMA; Selegiline; TV3326

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENSERAZIDE; BROFAROMINE; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; CLORGYLINE; DECARBOXYLASE INHIBITOR; DOPAMINE; LADOSTIGIL; LAZABEMIDE; LEVODOPA; MILACEMIDE; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; N PROPARGYLAMINOINDAN 5 YLETHYLMETHYLCARBAMATE HEMITARTATE; NORADRENALIN; RASAGILINE; RIVASTIGMINE; SELEGILINE; SEROTONIN; TYRAMINE; UNCLASSIFIED DRUG;

AKINESIA; ALZHEIMER DISEASE; BASAL GANGLION; BINDING SITE; BLOOD BRAIN BARRIER; BRADYKINESIA; BRAIN NERVE CELL; CHOLINERGIC TRANSMISSION; COGNITION; DEPRESSION; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINE RELEASE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME LOCALIZATION; EXTRAPYRAMIDAL SYMPTOM; HORMONE METABOLISM; HUMAN; HYPERTENSIVE CRISIS; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LEWY BODY; MOTOR ACTIVITY; MOTOR PERFORMANCE; NERVE ENDING; NONHUMAN; NORADRENALIN BRAIN LEVEL; NORADRENALIN RELEASE; PARKINSON DISEASE; PRIORITY JOURNAL; RAPHE NUCLEUS; REVIEW; SEROTONIN BRAIN LEVEL; SIDE EFFECT;

GYMNOMYZA SAMOENSIS;

EID: 0347415712     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(03)00103-7     Document Type: Article

References (49)

1. Allain H, Lieury A et al. Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline. Psychopharmacology 1993;106(Suppl):56-61.
2. Amrein R, Martin JR et al. Moclobemide in patients with dementia and depression. Adv Neurol 1999;80:509-19.
3. Bieck PR, Antonin KH et al. Clinical pharmacology of reversible monoamine oxidase-A inhibitors. Clin Neuropharmacol 1993;16(Suppl 2):S34-41.
4. Birkmayer W, Riederer P et al. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B Deprenil. J Neural Transm 1975;36(3-4):303-26.
5. Birkmayer W, Riederer P et al. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet 1977;1(8009):439-43.
6. Burn DJ. Depression in Parkinson's disease. Eur J Neurol 2002;9(s3):44.
7. Cesura AM, Pletscher A. The new generation of monoamine oxidase inhibitors. Prog Drug Res 1992;38:171-297.
8. Collins GG, Sandler M et al. Multiple forms of human brain mitochondrial monoamine oxidase. Nature 1970;225(235):817-20.
9. Colzi A, d'Agostini F et al. Brain microdialysis in rats: a technique to reveal competition in vivo between endogenous dopamine and moclobemide, a RIMA antidepressant. Psychopharmacology (Berl) 1992;106(Suppl):S17-20.
10. Da Prada M, Zurcher G, et al. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm 1987;26(Suppl):31-56.
11. Fairweather DB, Kerr JS et al. The effects of moclobemide on psychomotor performance and cognitive function. Int Clin Psychopharmacol 1993;8(1):43-7.
12. Finberg JP, Tenne M. Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br J Pharmacol 1982;77(1):13-21.
13. Finberg J, Youdim MBH. Pharmacological properties of the anti-Parkinson drug rasagiline: modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 2002;43(7):1110-8.
14. Finberg JP, Tenne M et al. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B. Br J Pharmacol 1981;73(1):65-74.
15. Green AR, Youdim MBH. Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol 1975;55(3):415-22.
16. Green AR, Mitchell BD et al. Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxy-tryptamine. Br J Pharmacol 1977;60(3):343-9.
17. Group PS. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989;321(20):1364-71.
18. Group PS. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328(3):176-83.
19. Group PS. A controlled trial of rasagiline in early Parkinson disease. Arch Neurol 2002;59:12.
20. Haefely W, Burkard WP et al. Biochemistry and pharmacology of moclobemide, a prototype RIMA. Psychopharmacology (Berl) 1992;106(Suppl):S6-S 14.
21. Honig LS, Mayeux R. Natural history of Alzheimer's disease. Aging (Milano) 2001;13(3):171-82.
22. Illi A, Sundberg S et al. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther 1996;59(4):450-7.
23. Jansen Steur EN, Ballering LA. Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease. Adv Neurol 1999;80:505-8.
24. Johnson JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968;17:1285-97.
25. Kalir A, Sabbagh A et al. Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. Br J Pharmacol 1981;73(1):55-64.
26. Kerr JS, Fairweather DB, et al. The effects of acute and repeated doses of moclobemide on psychomotor performance and cognitive function in healthy elderly volunteers. Hum Psychopharmacol: Clin Exp 1992;7:273-9.
27. Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol 1972;5:393-408.
28. Kom A, Da Prada M, et al. Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. J Neural Transm 1987;26(Suppl):57-71.
29. Lees AJ, Shaw KM et al. Deprenyl in Parkinson's disease. Lancet 1977;2(8042):791-5.
30. Newman SC. The prevalence of depression in Alzheimer's disease and vascular dementia in a population sample. J Affect Disord 1999;52(1-3):169-76.
31. O'Carroll AM, Fowler CJ et al. The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn-Schmiedebergs Arch Pharmacol 1983;322(3):198-202.
32. Palmer AM, Stratmann GC et al. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease. Ann Neurol 1988;23(6):616-20.
33. Porsolt RD, Bertin A et al. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229(2):327-36.
34. Riederer P, Youdim MBH. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with L-deprenyl. J Neurochem 1986;46(5):1359-65.
35. Riederer P, Konradi C. Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl. Adv Neurol 1987;45:111-8.
36. Ruggieri S, Fabbrini G et al. An open study with reversible MAO-A inhibitors in complicated Parkinson's disease. Adv Neurol 1996;69:595-8.
37. Sieradzan K, Channon S et al. The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease. J Clin Psychopharmacol 1995;15(4 Suppl 2):51S-9S.
38. Sternic N, Kacar A et al. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease. Clin Neuropharmacol 1998;21(2):93-6.
39. Steur EN, Ballering LA. Moclobemide and selegeline in the treatment of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63(4):547.
40. Tandberg E, Larsen JP et al. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 1996;53(2):175-9.
41. Tsolaki M, Kokarida K et al. Extrapyramidal symptoms and signs in Alzheimer's disease: prevalence and correlation with the first symptom. Am J Alzheimer's Dis Other Demen 2001;16(5): 268-78.
42. Weinstock M, Goren T et al. Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Dev Res 2000;50:216-22.
43. Weinstock M, Poltyrev T, et al. TV3326, a novel cholinesterase and MAO inhibitor for Alzheimer's disease with co-morbidity of Parkinson's disease and depression. In: Mizuno Y, Fisher A, Hanin I, editors. Mapping the progress of Alzheimer's and Parkinson's disease. New York: Kluwer Academic Publishers/ Plenum Press; 2002a. p. 199-204.
44. Weinstock M, Poltyrev T et al. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology (Berl) 2002b; 160(3):318-24.
45. Wesnes KA, Simpson PM et al. The effects of moclobemide on cognition. J Neural Transm Suppl 1989;28:91-102.
46. Youdim MBH, Riederer P. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J Neural Transm Gen Sect 1993;91(2-3):181-95.
47. Youdim MBH, Collins GG et al. Human brain monoamine oxidase: multiple forms and selective inhibitors. Nature 1972;236(5344):225-8.
48. Youdim MBH, Finberg JPM, et al. Monoamine oxidase. Catecholamine II. In: Trendelenburg U, Weiner N, editors. Handbook of experimental pharmacology. Berlin: Springer; 1988. p. 127-99.
49. Youdim MBH, Gross A et al. Rasagiline [N-Propargyl-1R(+)-aminoindant], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001;132:500-6.